EGFR and non-small cell lung carcinoma: However, when treated HCC2279 cells combination of erlotinib and ABT-737 remarkably enhanced BIM expression and cleaved caspase-3 (Figure 6E), thereby re-sensitizing NSCLC cells expressing EGFR-mutant and harboring the BIM deletion polymorphism to apoptosis.